Meeting
2022 ASCO Annual Meeting
Trial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: Addition of a new cohort with first-line (1L) tisotumab vedotin (TV) + pembrolizumab (pembro) + carboplatin (carbo) ± bevacizumab (bev) in recurrent/metastatic cervical cancer (r/mCC).
Authors
Ignace Vergote
Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Leuven Cancer Institute, and University Hospital Leuven, Leuven, Belgium
Ignace Vergote , Mansoor Raza Mirza , Jalid Sehouli , Domenica Lorusso , Fatih Köse , David Cibula , Anneke M. Westermann , Dearbhaile Catherine Collins , Susana N. Banerjee , Ana Oaknin , Ibrahima Soumaoro , Shweta Jain , Bradley J. Monk
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Cervical Cancer
Clinical Trial Registration Number
NCT03786081
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS5603)
DOI
10.1200/JCO.2022.40.16_suppl.TPS5603
Abstract #
TPS5603
Poster Bd #
478a
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase Ib/II trial of tisotumab vedotin (TV) ± bevacizumab (BEV), pembrolizumab (PEM), or carboplatin (CBP) in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8/GOG-3024).
First Author: Ignace Vergote
Poster
2019 ASCO Annual Meeting
KEYNOTE-826: a phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.
First Author: Ronnie Shapira-Frommer
First Author: Ana Oaknin
Poster
2023 ASCO Annual Meeting
The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.
First Author: Jianqing Zhu